WHO/iVB.11.09
WHO manual, 2nd edition
В этой брошюре рассказывается о том, что такое бактериальный менингит (т.е. менингит,
который вызван бактериями Neisseria ...t medbox">meningitides, Streptococcus pneumoniae, и
Haemophilus influenzae) и каковы его симптомы. В ней также объясняется, как распространяется эта болезнь и предлагаются профилактические меры по защите населения от заражения ею. Чтобы подробнее узнать о менингите, посетите интернетный сайт: www.cdc.gov/ncidod/diseases/submenus/sub_meningitis.htm
more
28 Sept. 2021
The focus of this fact sheet is on the four main causes of acute bacterial meningitis:
Neisseria meningitidis (meningococcus)
Streptococcus pneumoniae (pneumococcus)
...Haemophilus influenzae
Streptococcus agalactiae (group B streptococcus)
more
WHO Guideline. Since 2010, countries in the meningitis belt have started to introduce a new serogroup A meningococcal conjugate vaccine conferring individual protection and herd immunity. Following the successful roll-out of this vaccine, epidemics due to ...Neisseria meningitidis serogroup A (NmA) are disappearing, but other serogroups (e.g. NmW, NmX and NmC) still cause epidemics, albeit at a lower frequency and of a smaller size. Due to these changes, WHO organized the review of the evidence to provide recommendations for epidemic control, related to operational thresholds for investigation and response to outbreaks, the use of rapid diagnostic tests, antibiotic regimens in epidemics, and prophylaxis for household contacts of cases
more
Prevention, early diagnosis, and effective treatment are essential for the control and elimination of Neisseria gonorrhoeae as a public health problem. Currently, in Latin America and the Caribbean, treatment for gonorrhea infection is largely empir...ic and based on clinical diagnosis. In the Americas, the high burden of new N. gonorrhoeae infections (estimated at 11 million new cases a year), the complexity of the disease epidemiology, and in many countries the limited resources, make it difficult to fully understand the burden of disease and the burden of antimicrobial resistance (AMR) in N. gonorrhoeae.
PAHO has developed this document to facilitate the navigation of available guidance and recommendations for N. gonorrhoeae AMR surveillance by public health and health care professionals, at the national and subnational levels, involved in designing, implementing, and/or strengthening AMR surveillance of N. gonorrhoeae and overall surveillance of sexually transmitted infections.
more
Development of one or more vaccines for Neisseria gonorrhoeae is an important objective for sexual and reproductive health worldwide, and for the fight against antimicrobial resistance.
WHO preferred product characteristics (PPCs) provide strateg...ic guidance as to WHO’s preferences for new vaccines in priority disease areas. PPCs are intended to encourage innovation and development of vaccines for use in settings most relevant to the global unmet public health need.
Gonococcal vaccine PPCs describe global public health goals for gonococcal vaccines and preferred parameters pertaining to vaccine indications and target populations, safety and efficacy considerations, and immunization strategies.
more
RBC/IHDPC/ EID Division | November2011 - The aim of the standard operating procedures is to guide health care providers and public health
experts from various levels of the health system in the implementation of enhanced surveillance of meningococcal meningitis.
Defeating meningitis by 2030: a global road map
Int J Crit Illn Inj Sci. 2012 May-Aug; 2(2): 82–97.
doi: 10.4103/2229-5151.97273
PMCID: PMC3401822
PMID: 22837896
Report for WHO Meningitis guideline revision
Dr Thomas Waite, April 2014
Field Epidemiology Services, Public Health England; UK
WHO practical guidelines. 2nd edition
A quick reference guide for health authorities and health-care workers
Revised 2015